近日,全球领先的生物制药公司诺和诺德宣布,注射用培妥罗凝血素α(商品名:诺易特®)在中国大陆正式上市。诺易特®是我国首个且目前唯一*获批的长效重组凝血因子Ⅷ,且已成功被新版国家医保目录新增纳入。诺易特®在中国大陆市场的全面上市填补了血友病A长效治疗的空白,进一步提升了患者用药的可及性,将中国血友病A患者带入全新治疗阶段。 血友病是一种X染色体连锁的隐性遗传性出血性疾病,可分为血友病A和血友病B...
Source Link近日,全球领先的生物制药公司诺和诺德宣布,注射用培妥罗凝血素α(商品名:诺易特®)在中国大陆正式上市。诺易特®是我国首个且目前唯一*获批的长效重组凝血因子Ⅷ,且已成功被新版国家医保目录新增纳入。诺易特®在中国大陆市场的全面上市填补了血友病A长效治疗的空白,进一步提升了患者用药的可及性,将中国血友病A患者带入全新治疗阶段。 血友病是一种X染色体连锁的隐性遗传性出血性疾病,可分为血友病A和血友病B...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.